Keeping Up With The Newest Guideline Directed Medical Therapy For CHF: Resident-driven Quality Improvement Project
Konstantin Golubykh,Kripa Rajak,Aslan Amirian,Seema Sharma Gautam,Iuliia Kovalenko,Anupam Halder,Jesus Vargas,Roberto Hodara Friedmann,Yijin Wert,Kriti Taneja
DOI: https://doi.org/10.1016/j.cardfail.2023.10.448
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Chronic heart failure (CHF) is an epidemic associated with high morbidity and mortality. 2022 AHA/ACC/HFSA Guidelines for the Management of Heart Failure with reduced ejection fraction (HFrEF) include angiotensin receptor-neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA) and Sodium-glucose co-transporter 2 inhibitors (SGLT2I) as class 1 recommendations. However, guideline directed medical therapy (GDMT) for HFrEF remains underused. In light of the new guidelines for HFrEF and suboptimal prescription rate of GDMT, we decided to perform Quality Improvement project to improve the GDMT prescription rate. Methods: Our project included following interventions: dot phrase creation for all physicians through electronic medical records (EMR) system dedicated to patients admitted for HFrEF, educational sessions on the monthly hospitalists meetings, monthly emails and weekly EMR chat messages regarding GDMT and CHF order set to physicians, A4 sized posters distributed on all hospital floors. We then performed retrospective review and analysis of patients’ charts who were admitted to 3 UPMC Central PA hospitals with diagnosis of HFrEF exacerbation during March 2022 to May 2022 (preintervention) and July 2022 to September 2022 (postintervention). Results: Total of 359 patients were included. There were no significant differences in demographics between preintervention (197) and postintervention (159) groups including age, sex, race, number of previous admissions for HFrEF during past year and length of hospital stay. We did not find significant differences in prescription rate of BB between groups (89.95% vs 89.87%, p=0.876), but more patients had therapeutic dosages prescribed on discharge (3.49% vs 9.29%, p<0.0001). Prescription rate of ACEIs/ARBs was also equal (28.43% vs 20.75%, p=0.2526) but more patients were discharged on therapeutic dosages (9.43% vs 13.51%). There were no differences in ARNIs prescription rate (28.43% vs 20.75%, p=0.0628) with higher number of patients discharged on therapeutic dosages (10,71% vs 15,15%, p<0.0001). MRA had the same prescription rates (42.64% vs 47.17%, p=0.6586). However, more patients were discharged on SGLT2 (34.52% vs 37.97%, p= 0.0413). Also, utilization of CHF order set improved from 81.22% to 90.51% (p=0.0139). Documentation of contraindications improved from 34.01% to 45.91% (p=0.0223) for ARNIs and from 31.98% to 41.77% for SGLT2 (p=0.041). Many patients were still discharged without certain GDMT medications in the absence of contraindications (CI): 3.16% for BB, 14.47% for ACEIs/ARBs, 27.04% for ARNIs, 13.21% for MRA and 17.09% for SGLT2. Conclusion: Despite higher awareness of GDMT and trend towards having more patients discharged on therapeutic dosages of GDMT, we still can observe that GDMT is very underused among patients with CHFrEF. Our results show that more emphasis should be placed on educating providers regarding the indications and contraindications as well as rapid up-titration safety of GDMT.
cardiac & cardiovascular systems